361 related articles for article (PubMed ID: 24155918)
1. Long chain fatty Acyl-CoA synthetase 4 is a biomarker for and mediator of hormone resistance in human breast cancer.
Wu X; Li Y; Wang J; Wen X; Marcus MT; Daniels G; Zhang DY; Ye F; Wang LH; Du X; Adams S; Singh B; Zavadil J; Lee P; Monaco ME
PLoS One; 2013; 8(10):e77060. PubMed ID: 24155918
[TBL] [Abstract][Full Text] [Related]
2. ACSL4 promotes prostate cancer growth, invasion and hormonal resistance.
Wu X; Deng F; Li Y; Daniels G; Du X; Ren Q; Wang J; Wang LH; Yang Y; Zhang V; Zhang D; Ye F; Melamed J; Monaco ME; Lee P
Oncotarget; 2015 Dec; 6(42):44849-63. PubMed ID: 26636648
[TBL] [Abstract][Full Text] [Related]
3. Acyl-CoA synthetase-4 is implicated in drug resistance in breast cancer cell lines involving the regulation of energy-dependent transporter expression.
Orlando UD; Castillo AF; Medrano MAR; Solano AR; Maloberti PM; Podesta EJ
Biochem Pharmacol; 2019 Jan; 159():52-63. PubMed ID: 30414939
[TBL] [Abstract][Full Text] [Related]
4. Association of long-chain acyl-coenzyme A synthetase 5 expression in human breast cancer by estrogen receptor status and its clinical significance.
Yen MC; Kan JY; Hsieh CJ; Kuo PL; Hou MF; Hsu YL
Oncol Rep; 2017 Jun; 37(6):3253-3260. PubMed ID: 28498416
[TBL] [Abstract][Full Text] [Related]
5. Acyl-CoA synthetase-4, a new regulator of mTOR and a potential therapeutic target for enhanced estrogen receptor function in receptor-positive and -negative breast cancer.
Orlando UD; Castillo AF; Dattilo MA; Solano AR; Maloberti PM; Podesta EJ
Oncotarget; 2015 Dec; 6(40):42632-50. PubMed ID: 26536660
[TBL] [Abstract][Full Text] [Related]
6. Quadruple negative breast cancer.
Huang M; Wu J; Ling R; Li N
Breast Cancer; 2020 Jul; 27(4):527-533. PubMed ID: 31939077
[TBL] [Abstract][Full Text] [Related]
7. The functional interaction between Acyl-CoA synthetase 4, 5-lipooxygenase and cyclooxygenase-2 controls tumor growth: a novel therapeutic target.
Orlando UD; Garona J; Ripoll GV; Maloberti PM; Solano ÁR; Avagnina A; Gomez DE; Alonso DF; Podestá EJ
PLoS One; 2012; 7(7):e40794. PubMed ID: 22808264
[TBL] [Abstract][Full Text] [Related]
8. New inhibitor targeting Acyl-CoA synthetase 4 reduces breast and prostate tumor growth, therapeutic resistance and steroidogenesis.
Castillo AF; Orlando UD; Maloberti PM; Prada JG; Dattilo MA; Solano AR; Bigi MM; Ríos Medrano MA; Torres MT; Indo S; Caroca G; Contreras HR; Marelli BE; Salinas FJ; Salvetti NR; Ortega HH; Lorenzano Menna P; Szajnman S; Gomez DE; Rodríguez JB; Podesta EJ
Cell Mol Life Sci; 2021 Mar; 78(6):2893-2910. PubMed ID: 33068124
[TBL] [Abstract][Full Text] [Related]
9. Functional interaction between acyl-CoA synthetase 4, lipooxygenases and cyclooxygenase-2 in the aggressive phenotype of breast cancer cells.
Maloberti PM; Duarte AB; Orlando UD; Pasqualini ME; Solano AR; López-Otín C; Podestá EJ
PLoS One; 2010 Nov; 5(11):e15540. PubMed ID: 21085606
[TBL] [Abstract][Full Text] [Related]
10. Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance.
Leary AF; Drury S; Detre S; Pancholi S; Lykkesfeldt AE; Martin LA; Dowsett M; Johnston SR
Clin Cancer Res; 2010 Mar; 16(5):1486-97. PubMed ID: 20179226
[TBL] [Abstract][Full Text] [Related]
11. Regulatory mechanisms leading to differential Acyl-CoA synthetase 4 expression in breast cancer cells.
Dattilo MA; Benzo Y; Herrera LM; Prada JG; Castillo AF; Orlando UD; Podesta EJ; Maloberti PM
Sci Rep; 2019 Jul; 9(1):10324. PubMed ID: 31311992
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
[TBL] [Abstract][Full Text] [Related]
13. 17β-estradiol-induced ACSL4 protein expression promotes an invasive phenotype in estrogen receptor positive mammary carcinoma cells.
Belkaid A; Ouellette RJ; Surette ME
Carcinogenesis; 2017 Apr; 38(4):402-410. PubMed ID: 28334272
[TBL] [Abstract][Full Text] [Related]
14. Expression of Long-chain Fatty Acyl-CoA Synthetase 4 in Breast and Prostate Cancers Is Associated with Sex Steroid Hormone Receptor Negativity.
Monaco ME; Creighton CJ; Lee P; Zou X; Topham MK; Stafforini DM
Transl Oncol; 2010 Apr; 3(2):91-8. PubMed ID: 20360933
[TBL] [Abstract][Full Text] [Related]
15. Tumor-suppressive functions of long-chain acyl-CoA synthetase 4 in gastric cancer.
Ye X; Zhang Y; Wang X; Li Y; Gao Y
IUBMB Life; 2016 Apr; 68(4):320-7. PubMed ID: 26949059
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
Shou J; Massarweh S; Osborne CK; Wakeling AE; Ali S; Weiss H; Schiff R
J Natl Cancer Inst; 2004 Jun; 96(12):926-35. PubMed ID: 15199112
[TBL] [Abstract][Full Text] [Related]
17. Transient over-expression of estrogen receptor-α in breast cancer cells promotes cell survival and estrogen-independent growth.
Tolhurst RS; Thomas RS; Kyle FJ; Patel H; Periyasamy M; Photiou A; Thiruchelvam PT; Lai CF; Al-Sabbagh M; Fisher RA; Barry S; Crnogorac-Jurcevic T; Martin LA; Dowsett M; Charles Coombes R; Kamalati T; Ali S; Buluwela L
Breast Cancer Res Treat; 2011 Jul; 128(2):357-68. PubMed ID: 20730598
[TBL] [Abstract][Full Text] [Related]
18. Hedgehog Acyltransferase as a target in estrogen receptor positive, HER2 amplified, and tamoxifen resistant breast cancer cells.
Matevossian A; Resh MD
Mol Cancer; 2015 Apr; 14():72. PubMed ID: 25889650
[TBL] [Abstract][Full Text] [Related]
19. Long-Chain Acyl-CoA Synthetase 4-Mediated Fatty Acid Metabolism Sustains Androgen Receptor Pathway-Independent Prostate Cancer.
Ma Y; Zhang X; Alsaidan OA; Yang X; Sulejmani E; Zha J; Beharry Z; Huang H; Bartlett M; Lewis Z; Cai H
Mol Cancer Res; 2021 Jan; 19(1):124-135. PubMed ID: 33077484
[TBL] [Abstract][Full Text] [Related]
20. Acquired resistance to endocrine treatments is associated with tumor-specific molecular changes in patient-derived luminal breast cancer xenografts.
Cottu P; Bièche I; Assayag F; El Botty R; Chateau-Joubert S; Thuleau A; Bagarre T; Albaud B; Rapinat A; Gentien D; de la Grange P; Sibut V; Vacher S; Hatem R; Servely JL; Fontaine JJ; Decaudin D; Pierga JY; Roman-Roman S; Marangoni E
Clin Cancer Res; 2014 Aug; 20(16):4314-25. PubMed ID: 24947930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
